Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 204

1.

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group.; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif..

Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016.

PMID:
26917043
2.

Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.

Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, Chanteloup E, Seksik P, Baudry C, Flamant M, Bouguen G, Stefanescu C, Bourrier A, Bommelaer G, Dib N, Bigard MA, Viennot S, Hébuterne X, Gornet JM, Marteau P, Bouhnik Y, Abitbol V, Nahon S; GETAID..

J Crohns Colitis. 2016 Oct;10(10):1179-85. doi: 10.1093/ecco-jcc/jjw129.

PMID:
27402916
3.

Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.

Bayerdörffer E, Bigard MA, Weiss W, Mearin F, Rodrigo L, Dominguez Muñoz JE, Grundling H, Persson T, Svedberg LE, Keeling N, Eklund S.

BMC Gastroenterol. 2016 Apr 14;16:48. doi: 10.1186/s12876-016-0448-x.

4.

Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.

Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, Peyrin-Biroulet L.

Am J Gastroenterol. 2015 Aug;110(8):1186-96. doi: 10.1038/ajg.2015.205.

PMID:
26195181
5.

Prevalence of esophageal squamous papilloma (ESP) and associated cancer in northeastern France.

d'Huart MC, Chevaux JB, Bressenot AM, Froment N, Vuitton L, Degano SV, Latarche C, Bigard MA, Courrier A, Hudziak H, Koch S, Kull E, Peyrin-Biroulet L.

Endosc Int Open. 2015 Apr;3(2):E101-6. doi: 10.1055/s-0034-1390976.

6.

Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.

Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Guéant JL, Bronowicki JP, Peyrin-Biroulet L.

Eur J Gastroenterol Hepatol. 2015 Aug;27(8):877-81. doi: 10.1097/MEG.0000000000000370.

PMID:
26121376
7.

Beliefs and behaviour about smoking among inflammatory bowel disease patients.

Saadoune N, Peyrin-Biroulet L, Baumann C, Bigard MA, Wirth N, Martinet Y, Peyrin-Biroulet C.

Eur J Gastroenterol Hepatol. 2015 Jul;27(7):797-803. doi: 10.1097/MEG.0000000000000371.

PMID:
25919776
8.

Easy clip to treat anal fistula tracts: a word of caution.

Gautier M, Godeberge P, Ganansia R, Bozio G, Godart B, Bigard MA, Barthet M, Siproudhis L; Groupe de Recherche en Proctologie SNFCP France..

Int J Colorectal Dis. 2015 May;30(5):621-4. doi: 10.1007/s00384-015-2146-5.

PMID:
25675886
9.

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators..

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029.

PMID:
24480677
10.

Self-insertion of a nasogastric tube for home enteral nutrition: a pilot study.

Quilliot D, Zallot C, Malgras A, Germain A, Bresler L, Ayav A, Bigard MA, Peyrin-Biroulet L, Ziegler O.

JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):895-900. doi: 10.1177/0148607113502544.

PMID:
24142673
11.

Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.

Babouri A, Roblin X, Filippi J, Hébuterne X, Bigard MA, Peyrin-Biroulet L.

J Crohns Colitis. 2014 Feb;8(2):161-5. doi: 10.1016/j.crohns.2013.08.004.

PMID:
23994253
12.

The extra burden of infliximab infusions in inflammatory bowel disease.

Buisson A, Seigne AL, Dʼhuart MC, Bigard MA, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2013 Oct;19(11):2464-7. doi: 10.1097/MIB.0b013e3182a19268.

PMID:
23942563
13.

Submucosal plexitis as a predictor of postoperative surgical recurrence in Crohn's disease.

Bressenot A, Chevaux JB, Williet N, Oussalah A, Germain A, Gauchotte G, Wissler MP, Vignaud JM, Bresler L, Bigard MA, Plénat F, Guéant JL, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2013 Jul;19(8):1654-61. doi: 10.1097/MIB.0b013e318281f336.

PMID:
23751396
14.

Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.

Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):975-81.e1-4. doi: 10.1016/j.cgh.2012.12.042.

PMID:
23376316
15.

Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre.

Buisson A, Chevaux JB, Hudziak H, Bresler L, Bigard MA, Peyrin-Biroulet L.

Dig Liver Dis. 2013 Jul;45(7):569-72. doi: 10.1016/j.dld.2012.11.012.

PMID:
23298761
16.

Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease.

Cloché V, Buisson A, Tréchot F, Batta B, Locatelli A, Favel C, Premy S, Collet-Fenetrier B, Fréling E, Lopez A, Massoure MP, Humbert AL, Hansmannel F, Guéant JL, Bigard MA, Peyrin-Biroulet L, Angioi K.

Dig Liver Dis. 2013 Mar;45(3):195-9. doi: 10.1016/j.dld.2012.10.013.

PMID:
23200464
17.

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators..

Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096.

PMID:
23081753
18.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators..

Gastroenterology. 2012 Sep;143(3):608-18.e1-5. doi: 10.1053/j.gastro.2012.05.011.

PMID:
22626609
19.

[Risk factors of upper gastrointestinal complications in outpatients on antiplatelet therapy: description and management].

Ducrocq G, Bigard MA, Marouene S, Delaage PH, Fabry C, Barthelemy P, Steg PG; investigateurs CAAP (Évaluation des facteurs de risque de complications digestives des patients sous antiagrégant plaquettaire suivis en cardiologie de ville)..

Ann Cardiol Angeiol (Paris). 2012 Aug;61(4):245-51. doi: 10.1016/j.ancard.2012.01.004. French.

PMID:
22579299
20.

Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.

Babouri A, Buisson A, Bigard MA, Peyrin-Biroulet L.

J Crohns Colitis. 2013 Mar;7(2):129-33. doi: 10.1016/j.crohns.2012.03.007.

PMID:
22472090

Supplemental Content

Loading ...
Support Center